Pilot study of the transdermal application of testosterone gel to the penile skin for the treatment of hypogonadotropic men with erectile dysfunction

Schultheiss, Dirk; Hiltl, Dirk-Michael; Meschi, Mohammad R.; Machtens, Stefan A.; Truss, Michael C.; Stief, Christian G.; Jonas, Udo
December 2000
World Journal of Urology;Dec2000, Vol. 18 Issue 6, p431
Academic Journal
Androgens influence important central and peripheral mechanisms of the erectile system. The relevance of a moderate decrease of serum testosterone level for erectile dysfunction (ED) has not been clarified so far. The aim of our study was to offer an easy transcutaneous method of androgen application. A previous study on the pharmacokinetic profile of the testosterone gel applied, showed marked elevation of the serum levels of testosterone. In our study, 46 hypogonadal patients with ED and total lack of vaginal penetration applied testosterone gel (4 mg/day; supplied by Azupharma, Germany) to the penile skin twice a day over 6–8 weeks, after a run-in period with placebo gel of 2 weeks. All patients showed decreased testosterone serum levels (<3 ng/ml) in at least two morning samples over a period of 3 weeks before treatment. Psychogenic etiology was excluded by a sexual psychologist. Patient age was 37–69 years (mean 53.5). Three patients (6.5%) responded to placebo in the run-in phase and were withdrawn from further treatment. Fifteen patients (32.6%) showed improved erection, allowing penetration and sexual intercourse. Twenty-eight patients (60.9%) did not respond to therapy. Local genital skin irritation was not observed. Elevation of peripheral testosterone was not correlated to a positive therapy response. A success-rate of 32.6% in this group of patients after exclusion of psychogenic patients and placebo-responders seems to justify further investigations. A medication period of 6–8 weeks is most probably too short to induce imaginable regenerative effects of testosterone on the erectile system. We therefore suggest that future double-blind and placebo-controlled studies should be designed for a minimum of 3 months. Testosterone gel may be a cost effective form of androgen administration.


Related Articles

  • Androgen Therapy Increases Propeptide of Type I Collagen in Women with Anorexia Nervosa.  // Eating Disorders Review;Jan/Feb2005, Vol. 16 Issue 1, p6 

    Reports on the treatment of bone loss and bone density among hypogonadal men and postmenopausal women with low-dose of androgen therapy. Treatment among women with transdermal testosterone or placebo; Side effects of testosterone on women; Need for more experimental study on the efficacy of...

  • Testosterone May Not Improve ED. Schieszer, John // Renal & Urology News;Dec2011, Vol. 10 Issue 12, p1 

    The article reports on the result of a study which shows that supplementation of testosterone in older men with borderline low testosterone levels may not improve the treatment for erectile dysfunction (ED) compared with placebo.

  • A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia. Ekman, P. // Drug Safety;Mar1998, Vol. 18 Issue 3, p161 

    As an androgen target organ, the prostate gland has the almost unique characteristic of being less sensitive to testosterone than to its metabolite 5α-dihydrotestosterone (5α-DHT). The conversion of testosterone to 5α-DHT is induced by the enzyme 5α-reductase. By blocking the...

  • Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency. Kim, J W; Oh, M M; Park, M G; Park, J Y; Bae, J H; Kim, J J; Moon, D G // International Journal of Impotence Research;Jan/Feb2013, Vol. 25 Issue 1, p29 

    Several studies have suggested combination therapy with testosterone supplementation in patients not responding to PDE5 inhibitors. Considering the pathophysiological basis for testosterone supplementation, the present study aims to identify whether combination therapy allows persistence of...

  • Effect of Testosterone Replacement on Response to Sildenafil Citrate in Men With Erectile Dysfunction: A Parallel, Randomized Trial. Spitzer, Matthew; Basaria, Shehzad; Travison, Thomas G.; Davda, Maithili N.; Paley, Amanda; Cohen, Beth; Mazer, Norman A.; Knapp, Philip E.; Hanka, Samson; Lakshman, Kishore M.; Ulloor, Jagadish; Zhang, Anqi; Orwoll, Katie; Eder, Richard; Collins, Lauren; Mohammed, Nurahmed; Rosen, Raymond C.; DeRogatis, Leonard; Bhasin, Shalender // Annals of Internal Medicine;11/20/2012, Vol. 157 Issue 10, p681 

    Background: Erectile dysfunction and low testosterone levels frequently occur together. Objective: To determine whether addition of testosterone to sildenafil therapy improves erectile response in men with erectile dysfunction and low testosterone levels. Design: Randomized, double-blind,...

  • Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. Lin Xu; Freeman, Guy; Cowling, Benjamin J.; Schooling, C. Mary // BMC Medicine;2013, Vol. 11 Issue 1, p1 

    Background: Testosterone therapy is increasingly promoted. No randomized placebo-controlled trial has been implemented to assess the effect of testosterone therapy on cardiovascular events, although very high levels of androgens are thought to promote cardiovascular disease. Methods: A...

  • Korean Ginseng and Erectile Dysfunction. Bone, Kerry // Townsend Letter;Jan2008, Issue 294, p56 

    The article reports on the result of the study about the effect of Korean red ginseng root on men with erectile dysfunction in Brazil. The study was participated by patients treated with Korean red ginseng root and placebo with a dose of 3 grams per day for 12 weeks. According to the...

  • T FOR TU? Csatari, Jeffrey J. // Best Life;Oct2006, Vol. 3 Issue 8, p114 

    The article presents information on raising one's testosterone. The normal amount of testosterone in the bloodstream is between 300 and 1,000 nanograms per deciliter. Like brushable hair, T levels start to wane around age 40. One loses about 1 to 2 percent a year, but over time reduced male...

  • Testosterone patch nothing to get excited about, say reviewers. Brown, Simon // Menopause International;Jun2009, Vol. 15 Issue 2, p51 

    This article discusses a report on the use of the testosterone patch to treat women suffering from hypoactive sexual desire disorder (HSDD). Published in the March 2009 issue of "Drug and Therapeutics Bulletin," the report included studies of the testosterone patch. It also found a placebo...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics